2',5'-Riboadenylate-morpholinoadenylate nucleotides
First Claim
Patent Images
1. A nucleotide compound with a 2,5-internucleotide linkage having 1 to 15 riboseadenine unit and a terminal morpholine unit, having the formula ##STR5## wherein:
- Y is always H except on the terminal phosphate where Y may be H, adenosine, or a C1-20 primary or secondary alcohol;
m is 0, 1, 2, 3 or 4;
n is an integer from 1 to 15; and
Z is H or a C1-50 hydrocarbon or substituted hydrocarbon bonded through one of its C atoms to the N of the morpholino ring.
1 Assignment
0 Petitions
Accused Products
Abstract
Novel nucleotide compounds are afforded, having at least one 2'"'"',5'"'"'-riboadenylate unit and a terminal morpholinoadenylate unit. These compounds have potentiated biological activity in the 2,5-A system and increased resistance to degradation.
55 Citations
10 Claims
-
1. A nucleotide compound with a 2,5-internucleotide linkage having 1 to 15 riboseadenine unit and a terminal morpholine unit, having the formula ##STR5## wherein:
- Y is always H except on the terminal phosphate where Y may be H, adenosine, or a C1-20 primary or secondary alcohol;
m is 0, 1, 2, 3 or 4; n is an integer from 1 to 15; and Z is H or a C1-50 hydrocarbon or substituted hydrocarbon bonded through one of its C atoms to the N of the morpholino ring. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
- Y is always H except on the terminal phosphate where Y may be H, adenosine, or a C1-20 primary or secondary alcohol;
-
9. A method of blocking the action of interferon produced by animal cells comprising using as an antagonist an effective amount of a nucleotide compound with a 2,5-internucleotide linkage having 1 to 15 ribose-adenine unit and a terminal morpholine unit, having the formula ##STR6## wherein:
- Y is always H except on the terminal phosphate where Y may be H, adenosine, or a C1-20 primary or secondary alcohol;
m is 0, 1, 2, 3 or 4; n is an integer from 1 to 15; and Z is H or a C1-50 hydrocarbon or substituted hydrocarbon bonded through one of its C atoms to the N of the morpholino ring.
- Y is always H except on the terminal phosphate where Y may be H, adenosine, or a C1-20 primary or secondary alcohol;
-
10. A method of treating interferon-induced autoimmune disease comprising administering to a host having said disease a pharmaceutically effective amount of a nucleotide compound with a 2,5-internucleotide linkage having 1-15 ribose-adenine unit and a terminal morpholine unit, having the formula ##STR7## wherein:
- Y is always H except on the terminal phosphate where Y may be H, adenosine, or a C1-20 primary or secondary alcohol;
m is 0, 1, 2, 3 or 4; n is an integer from 1 to 15; and Z is H or a C1-50 hydrocarbon or substituted hydrocarbon bonded through one of its C atoms to the N of the morpholino ring; and a pharmaceutically acceptable carrier.
- Y is always H except on the terminal phosphate where Y may be H, adenosine, or a C1-20 primary or secondary alcohol;
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeUnited States Department Of Health And Human Services
-
Original AssigneeUnited States Department Of Health And Human Services
-
InventorsTorrence, Paul F., Imai, Jiro, Johnston, Margaret I.
-
Primary Examiner(s)Brown, Johnnie R.
-
Assistant Examiner(s)Peselev, Elli
-
Application NumberUS06/468,950Time in Patent Office804 DaysField of Search536/27, 536/28, 536/29, 424/180US Class Current514/44.00RCPC Class CodesA61P 35/00 Antineoplastic agentsA61P 37/00 Drugs for immunological or ...A61P 43/00 Drugs for specific purposes...C07H 19/20 with the saccharide radical...C07H 21/00 Compounds containing two or...
